Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 133 entries
View as:

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT03651947 Org: User:
Start: 08/20/18 End: 05/22/19 Due: 05/22/20

Lifitegrast Eye Drops in Healthy Subjects：Phase I Study

Phase: N/A Priority: Normal
NCT ID: NCT07040826 Org: User:
Start: 12/06/22 End: 04/10/23 Due: 04/10/24

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Phase: N/A Priority: Normal
NCT ID: NCT06949761 Org: User:
Start: 06/30/25 End: 06/30/27 Due: 06/30/28

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD)

Phase: N/A Priority: Normal
NCT ID: NCT05058118 Org: User:
Start: 12/08/19 End: 06/03/20 Due: 06/03/21

Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections

Phase: N/A Priority: Normal
NCT ID: NCT05060419 Org: User:
Start: 10/08/21 End: 08/31/22 Due: 08/31/23

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Phase: N/A Priority: Normal
NCT ID: NCT06406205 Org: User:
Start: 12/25/23 End: 06/30/28 Due: 06/30/29

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Phase: N/A Priority: Normal
NCT ID: NCT04632758 Org: User:
Start: 06/01/19 End: 12/01/24 Due: 12/01/25

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06394713 Org: User:
Start: 06/15/24 End: 12/15/26 Due: 12/15/27

A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06173011 Org: User:
Start: 12/12/23 End: 07/31/24 Due: 07/31/25

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05179317 Org: User:
Start: 05/30/21 End: 12/31/23 Due: 12/31/24

Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05823246 Org: User:
Start: 04/24/23 End: 07/31/24 Due: 07/31/25

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT04435652 Org: User:
Start: 07/01/20 End: 11/30/22 Due: 11/30/23

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05629949 Org: User:
Start: 04/29/20 End: 04/13/23 Due: 04/13/24

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05236621 Org: User:
Start: 01/04/21 End: 12/31/23 Due: 12/31/24

A Study of QLF3108 in Participants With Advanced Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT06019013 Org: User:
Start: 08/16/23 End: 12/31/25 Due: 12/31/26

Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD

Phase: N/A Priority: Normal
NCT ID: NCT03312283 Org: User:
Start: 12/20/17 End: 04/02/19 Due: 04/02/20

A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients

Phase: N/A Priority: Normal
NCT ID: NCT03244085 Org: User:
Start: 08/20/17 End: 12/30/18 Due: 12/30/19

A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05830045 Org: User:
Start: 05/19/23 End: 12/31/25 Due: 12/31/26

A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03557580 Org: User:
Start: 04/17/18 End: 05/18/18 Due: 05/18/19

A Phase I Study of QL1604 for Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05801094 Org: User:
Start: 07/20/20 End: 12/15/23 Due: 12/15/24

A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition

Phase: N/A Priority: Normal
NCT ID: NCT03435666 Org: User:
Start: 05/31/18 End: 11/30/18 Due: 11/30/19

A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT06058000 Org: User:
Start: 11/13/23 End: 09/30/24 Due: 09/30/25

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06446388 Org: User:
Start: 06/30/24 End: 12/01/27 Due: 12/01/28

Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05884801 Org: User:
Start: 06/30/23 End: 07/30/25 Due: 07/30/26

a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.

Phase: N/A Priority: Normal
NCT ID: NCT06789796 Org: User:
Start: 02/28/25 End: 03/31/30 Due: 03/31/31